Jaguar Health, Inc. — fact timeline

Jaguar Health, Inc. entered into Second Exchange Agreement with Streeterville Capital, LLC (effective 2026-06-01).

“On June 1, 2026, the Company entered into another privately negotiated exchange agreement with Streeterville (the “Second Exchange Agreement”), pursuant to which the Company issued 32,710 shares (the “Second Exchange Shares”) of Common Stock to Streeterville in exchange for an aggregate of 4.2 outstanding shares of Series Q Preferred Stock held by Streeterville (the “Second Exchanged Preferred Shares”).”

Jaguar Health, Inc. entered into First Exchange Agreement with Streeterville Capital, LLC (effective 2026-05-26).

“On May 26, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “First Exchange Agreement”), pursuant to which the Company issued 31,958 shares (the “First Exchange Shares”) of the Company’s common stock, par value $0.0001 (the “Common Stock”) to Streeterville in exchange for an aggregate of 3.72 outstanding shares of Series Q Preferred Stock held by Streeterville (the “First Exchanged Preferred Shares”).”

Jaguar Health, Inc. amended debt of $12 million with Streeterville Capital, LLC.

“22, 2020, Jaguar Health, Inc. (the “Company”) sold to Uptown Capital, LLC(f/k/a Irving Park Capital, LLC) (“Uptown”) a royalty interest in the original principal amount of $12 million (as amended, the “December 2020 Royalty Interest”). On May 19, 2026, the Company entered into a privately negotiated exchange agreement (the “Uptown Series Q Exchange Agreement”)”

Jaguar Health, Inc. amended debt of $12 million with Uptown Capital, LLC.

“22, 2020, Jaguar Health, Inc. (the “Company”) sold to Uptown Capital, LLC(f/k/a Irving Park Capital, LLC) (“Uptown”) a royalty interest in the original principal amount of $12 million (as amended, the “December 2020 Royalty Interest”). On May 19, 2026, the Company entered into a privately negotiated exchange agreement (the “Uptown Series Q Exchange Agreement”)”

Jaguar Health, Inc.: Filed Certificate of Designation for Series Q Preferred Stock, establishing preferences, rights, and limitations (effective 2026-05-19).

“The preferences, rights, limitations and other matters relating to the Series Q Preferred Stock are set forth in the Certificate of Designation, which the Company filed with the Secretary of State of the State of Delaware on May 19, 2026. The Certificate of Designation became effective with the Secretary of State of the State of Delaware upon filing.”

Jaguar Health, Inc. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(4), 5810(d), 5810(c)(3)(A)).

“May 1, 2026, Jaguar Health, Inc. (the “Company”) received a written notification (the “Notice”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying th”

Jaguar Health, Inc.: Filed Eleventh Amendment to Third Amended and Restated Certificate of Incorporation to effect a 1-for-35 reverse stock split (effective 2026-04-30).

“the Company filed the Eleventh Amendment with the Secretary of State of the State of Delaware. The Reverse Stock Split will become effective in accordance with the terms of the Eleventh Amendment at 12:01 am Eastern Time on April 30, 2026”

Jaguar Health, Inc. received a nasdaq hearing update notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv), 5810(c)(3)(A)).

“April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su”

Jaguar Health, Inc.: Tenth Amendment to the Certificate of Incorporation to increase authorized shares of voting common stock from 298,000,000 to 500,000,000 and total authorized shares from 352,475,074 to 554,475,074 (effective 2026-04-20).

“item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year. At a special meeting of stockholders of Jaguar Health, Inc. (the “Company”) held on April 20, 2026 (the “Special Meeting”), the Company’s stockholders approved an amendment (the “Tenth Amendment”) to the Company’s Third Amended and Restated Certificate of Incorporation (the “COI”) to effect an increase in the number of authorized shares of the Company’s voting common stock, par value $0.0001 per share (the “Common Stock”), from 298,000,000 shares to 500,000,000 shares and a corresponding increase in the total number of shares the Company is authorized to issue from 352,475,074 shares to 554,475,074 shares (the “Authorized Share Increase”).”

Jaguar Health, Inc. reported year ended December 31, 2025 results: revenue $11.5 million, net income $53.6 million net loss, EPS ($24.27) per share.

“the total net revenue in the fourth quarter of 2024, which totaled approximately $3.5 million. • In 2025, approximately $11.2 million out of the Company’s total net revenue of $11.5 million was generated by sales of Mytesi and Canalevia-CA1. Under the terms of the license agreement Jaguar entered with Future Pak (“FP”) in January 2026, FP will be responsible for all”

Jaguar Health, Inc. terminated Warrant Termination Agreement with Uptown Capital, LLC, Streeterville Capital, LLC, Iliad Research and Trading, L.P. (effective 2026-03-06).

“On March 6, 2026, the Company entered into a warrant termination agreement (the “Warrant Termination Agreement”) with Uptown, Streeterville, and Iliad Research and Trading, L.P. (“Iliad”; and together with Uptown and Streeterville, collectively the “Investors”), pursuant to which, warrants exercisable into an aggregate of 48,211 shares of the Company’s voting common stock, par value $0.0001 per share (the “Common Stock”) previously issued by the Company to the Investors would be terminated.”

Jaguar Health, Inc. amended 2025 Note Amendment with Streeterville Capital, LLC valued at $7,048,021.86 (effective 2026-03-06).

“On March 6, 2026, the Company also entered into an amendment (the “2025 Note Amendment”) with Streeterville to the secured promissory note in the original principal amount of $10,810,000.00 (the “2025 Note”) issued by the Company to Streeterville on November 12, 2025 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date.”

Jaguar Health, Inc. amended 2021 Note Amendment No. 3 with Streeterville Capital, LLC valued at $6,596,304.11 (effective 2026-03-06).

“On March 6, 2026, the Company and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary (“Napo” and together with the Company, the “Borrower”), entered into an amendment (the “2021 Note Amendment No. 3”) with Streeterville to the secured promissory note in the original principal amount of $6,220,812.50 (as amended, the “2021 Note”) issued by Borrower to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date.”

Jaguar Health, Inc. amended Streeterville 2022 Royalty Interest Global Amendment No. 4 with Streeterville Capital, LLC valued at $12,428,782.20 (effective 2026-03-06).

“On March 6, 2026, the Company also entered into an amendment (the “Streeterville 2022 Royalty Interest Global Amendment No. 4”) to the royalty interest in the original principal amount of $12 million, as amended (the “Streeterville 2022 Royalty Interest”) with Streeterville Capital, LLC (“Streeterville”), pursuant to which, (i) the starting date for the Company to make the monthly Royalty Payment under the Streeterville 2022 Royalty Interest would be postponed from April 1, 2026 to July 1, 2026, and (ii) the Royalty Repayment Amount (as defined in the Streeterville 2022 Royalty Interest) would be reduced by ten percent.”

Jaguar Health, Inc. amended Uptown 2020 Royalty Interest Global Amendment No. 4 with Uptown Capital, LLC valued at $11,125,282.54 (effective 2026-03-06).

“On March 6, 2026, Jaguar Health, Inc. (the “Company”) entered into an amendment (the “Uptown 2020 Royalty Interest Global Amendment No. 4”) to the royalty interest in the original principal amount of $12 million, as amended (the “Uptown 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), as amended, pursuant to which, (i) the starting date for the Company to make the monthly Royalty Payment under the Uptown 2020 Royalty Interest would be postponed from April 1, 2026 to July 1, 2026, and (ii) the Royalty Repayment Amount (as defined in the Uptown 2020 Royalty Interest) would be reduced by ten percent.”

Jaguar Health, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).

“March 5, 2026, Jaguar Health, Inc. (the “Company”) received a written notification (the “Notice”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that because the bid price for the Company’s common stock for the previous 30 consecutive business days had closed below the minimum $1.00 per share, the Company was no longer in compliance with the requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). Further, the Notice stated that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)”

Jaguar Health, Inc.: Filed Certificate of Designation for Series O Convertible Preferred Stock (effective 2026-03-02).

“on March 2, 2026 the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series O Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, to designate 1,557,000 shares of the Company’s preferred stock, par value $0.0001 per share, as Series O Convertible Preferred Stock”

Jaguar Health, Inc. entered into Streeterville Series M Exchange Agreement with Streeterville Capital, LLC valued at Issued a pre-funded common stock purchase warrant to purchase 2,270,765 shares of Common Stock in ex (effective 2026-01-16).

“On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “Streeterville Series M Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 2,270,765 shares of Common Stock (the “Sixth Pre-Funded Warrant”) to Streeterville in exchange for 69.44 shares of Series M Preferred Stock held by Streeterville.”

Jaguar Health, Inc. entered into Iliad Series M Exchange Agreement with Iliad Research and Trading, L.P. valued at Issued a pre-funded common stock purchase warrant to purchase 2,870,503 shares of Common Stock in ex (effective 2026-01-16).

“On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Iliad (the “Iliad Series M Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 2,870,503 shares of Common Stock (the “Fifth Pre-Funded Warrant”) to Iliad in exchange for 87.78 shares of Series M Preferred Stock held by Iliad.”

Jaguar Health, Inc. entered into Streeterville Series L Exchange Agreement with Streeterville Capital, LLC valued at Issued a pre-funded common stock purchase warrant to purchase 3,249,908 shares of Common Stock in ex (effective 2026-01-16).

“On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “Streeterville Series L Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 3,249,908 shares of Common Stock (the “Fourth Pre-Funded Warrant”) to Streeterville in exchange for 99.3822 shares of Series L Preferred Stock held by Streeterville.”

Jaguar Health, Inc. entered into Iliad Series L Exchange Agreement with Iliad Research and Trading, L.P. valued at Issued a pre-funded common stock purchase warrant to purchase 719,424 shares of Common Stock in exch (effective 2026-01-16).

“On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Iliad (the “Iliad Series L Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 719,424 shares of Common Stock (the “Third Pre-Funded Warrant”) to Iliad in exchange for 22 shares of Series L Preferred Stock held by Iliad.”

Jaguar Health, Inc. entered into Streeterville Royalty Interest Exchange Agreement with Streeterville Capital, LLC valued at Issued a pre-funded common stock purchase warrant to purchase 1,111,837 shares of Common Stock in ex (effective 2026-01-16).

“On January 16, 2026, the Company entered into a privately negotiated exchange agreement (the “Streeterville Royalty Interest Exchange Agreement”) with Streeterville.”

Jaguar Health, Inc. entered into Iliad Royalty Interest Exchange Agreement with Iliad Research and Trading, L.P. valued at Issued a pre-funded common stock purchase warrant to purchase 1,553,844 shares of Common Stock in ex (effective 2026-01-16).

“On January 16, 2026, the Company entered into a privately negotiated exchange agreement (the “Iliad Royalty Interest Exchange Agreement”) with Iliad.”

Jaguar Health, Inc. entered into Supply Agreement with Woodward Specialty LLC and Future Pak, LLC (effective 2026-01-12).

“Also on the Effective Date, Napo, Licensee and Future Pak entered into a manufacturing and supply agreement (the “Supply Agreement”)”

Jaguar Health, Inc. entered into License Agreement with Woodward Specialty LLC and Future Pak, LLC valued at $18 million (effective 2026-01-12).

“On January 12, 2026 (the “Effective Date”), Napo Pharmaceuticals, Inc. (“Napo”), a wholly-owned subsidiary of Jaguar Health, Inc., a Delaware corporation (the “Company”), and the Company, entered into a license agreement (the “License Agreement”) with Woodward Specialty LLC (the “Licensee”), an affiliate of Future Pak, LLC (“Future Pak”), and Future Pak”

Jaguar Health, Inc. entered into Securities Purchase Agreements with two accredited investors valued at $350,000 aggregate principal amount (effective 2026-01-06).

“On January 6, 2026 (the “Execution Date”), Jaguar Health, Inc. (the “Company”) entered into securities purchase agreements (the “Securities Purchase Agreements”) with two accredited investors (each, an “Investor”), pursuant to which the Company issued $350,000 aggregate principal amount of unsecured promissory notes (collectively, the “Notes”) to such Investors.”

Jaguar Health, Inc. entered into Securities Purchase Agreements with two accredited investors valued at $350,000 (effective 2026-01-05).

“On January 5, 2026 (the "Execution Date"), Jaguar Health, Inc. (the "Company") entered into securities purchase agreements (the "Securities Purchase Agreements") with two accredited investors (each, an "Investor"), pursuant to which the Company issued $350,000 aggregate principal amount of unsecured promissory notes”

Jaguar Health, Inc. entered into Securities Purchase Agreements with two accredited investors valued at $350,000 aggregate principal amount (effective 2026-01-06).

“On January 6, 2026 (the "Execution Date"), Jaguar Health, Inc. (the "Company") entered into securities purchase agreements (the "Securities Purchase Agreements") with two accredited investors (each, an "Investor"), pursuant to which the Company issued $350,000 aggregate principal amount of unsecured promissory notes (collectively, the "Notes") to such Investors.”

Jaguar Health, Inc. incurred loan of $350,000 aggregate principal amount with two accredited investors at 6% per annum maturing one month after issuance.

“On January 6, 2026 (the “Execution Date”), Jaguar Health, Inc. (the “Company”) entered into securities purchase agreements (the “Securities Purchase Agreements”) with two accredited investors (each, an “Investor”), pursuant to which the Company issued $350,000 aggregate principal amount of unsecured promissory notes (collectively, the “Notes”) to such Investors.”

Jaguar Health, Inc. incurred senior notes of $350,000 aggregate principal amount at 6% per annum maturing one month after issuance.

“On January 5, 2026 (the “Execution Date”), Jaguar Health, Inc. (the “Company”) entered into securities purchase agreements (the “Securities Purchase Agreements”) with two accredited investors (each, an “Investor”), pursuant to which the Company issued $350,000 aggregate principal amount of unsecured promissory notes (collectively, the “Notes”) to such Investors.”

Jaguar Health, Inc. incurred senior notes of $350,000 at 6% per annum maturing one month after issuance.

“On January 6, 2026 (the “Execution Date”), Jaguar Health, Inc. (the “Company”) entered into securities purchase agreements (the “Securities Purchase Agreements”) with two accredited investors (each, an “Investor”), pursuant to which the Company issued $350,000 aggregate principal amount of unsecured promissory notes (collectively, the “Notes”) to such Investors.”

Jaguar Health, Inc. amended loan with Streeterville Capital, LLC maturing April 1, 2026.

“On November 17, 2025, the Company and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary (“Napo” and together with the Company, the “Borrower”), entered into an amendment (the “Note Amendment No. 2”) with Streeterville to the secured promissory note in the original principal amount of $6,220,812.50 (as amended, the “Note”) issued by Borrower to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date (as amended, the “Note Purchase Agreement”). Pursuant to the Note Amendment No. 2, the maturity date of the Note is extended to April 1, 2026.”

Jaguar Health, Inc. amended debt with Streeterville Capital, LLC.

“On November 17, 2025, Jaguar Health, Inc. (the “Company”) entered into amendments (the “Royalty Interest Global Amendments No. 3”) to (i) the royalty interest in the original principal amount of $12 million (the “October 2020 Royalty Interest”) with Iliad Research and Trading, L.P. (“Iliad”), as amended, (ii) the royalty interest in the original principal amount of $12 million (the “December 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), as amended, and (iii) the royalty interest in the original principal amount of $12 million (the “August 2022 Royalty Interest” and, together with the October 2020 Royalty Interest and the December 2020 Royalty Interest, the “Royalty Interests”) with Streeterville Capital, LLC (“Streeterville” and, together with Iliad and Uptown, the “Investors”), pursuant to which, beginning on April 1, 2026, the monthly Royalty Payment under each of the Royalty Interests shall be the greater of (a) $750,000.00, and (b) the”

Jaguar Health, Inc. amended debt with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC).

“On November 17, 2025, Jaguar Health, Inc. (the “Company”) entered into amendments (the “Royalty Interest Global Amendments No. 3”) to (i) the royalty interest in the original principal amount of $12 million (the “October 2020 Royalty Interest”) with Iliad Research and Trading, L.P. (“Iliad”), as amended, (ii) the royalty interest in the original principal amount of $12 million (the “December 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), as amended, and (iii) the royalty interest in the original principal amount of $12 million (the “August 2022 Royalty Interest” and, together with the October 2020 Royalty Interest and the December 2020 Royalty Interest, the “Royalty Interests”) with Streeterville Capital, LLC (“Streeterville” and, together with Iliad and Uptown, the “Investors”), pursuant to which, beginning on April 1, 2026, the monthly Royalty Payment under each of the Royalty Interests shall be the greater of (a) $750,000.00, and (b) the”

Jaguar Health, Inc. amended debt with Iliad Research and Trading, L.P..

“On November 17, 2025, Jaguar Health, Inc. (the “Company”) entered into amendments (the “Royalty Interest Global Amendments No. 3”) to (i) the royalty interest in the original principal amount of $12 million (the “October 2020 Royalty Interest”) with Iliad Research and Trading, L.P. (“Iliad”), as amended, (ii) the royalty interest in the original principal amount of $12 million (the “December 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), as amended, and (iii) the royalty interest in the original principal amount of $12 million (the “August 2022 Royalty Interest” and, together with the October 2020 Royalty Interest and the December 2020 Royalty Interest, the “Royalty Interests”) with Streeterville Capital, LLC (“Streeterville” and, together with Iliad and Uptown, the “Investors”), pursuant to which, beginning on April 1, 2026, the monthly Royalty Payment under each of the Royalty Interests shall be the greater of (a) $750,000.00, and (b) the”

Jaguar Health, Inc. incurred loan of $10,810,000 with Streeterville Capital, LLC at 8.00% per annum maturing 36 months following the date of issuance.

“the Company issued and sold to the Lender a secured promissory note in the original principal amount of $10,810,000”

Jaguar Health, Inc.: Filed Series N Certificate of Designation for preferred stock (effective 2025-09-09).

“Series N Certificate of Designation As disclosed under Items 1.01 and 3.02 above, in connection with the Private Placement, the Company agreed to issue shares of Series N Preferred Stock to the Purchasers. The preferences, rights, limitations and other matters relating to the Series N Preferred Stock are set forth in the Certificate of Designation, which the Company filed with the Secretary of State of the State of Delaware on September 9, 2025.”

Jaguar Health, Inc.: Filed Series M Certificate of Designation for preferred stock, establishing terms, rights, and preferences (effective 2025-06-27).

“The preferences, rights, limitations and other matters relating to the Series M Preferred Stock are set forth in the Certificate of Designation, which the Company filed with the Secretary of State of the State of Delaware on June 27, 2025.”

Jaguar Health, Inc. incurred convertible notes of approximately $2.57 million aggregate principal amount with Participating Investors at 6% per annum maturing January 30, 2026.

“On June 24, 2025, the Company entered into note exchange and warrant purchase agreements (the “Exchange Agreements”) with certain of the Original Investors (the “Participating Investors”), pursuant to which the Company agreed to (a) issue and sell (i) approximately $2.57 million aggregate principal amount of new 6% convertible promissory notes (the “Replacement Notes”), in exchange for the cancellation of the Original Notes held by the Participating Investors”